- Home
- VZIO vs IOVA Comparison
VZIO vs IOVA Comparison
Compare VZIO & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VZIO
- IOVA
- Stock Information
- Founded
- VZIO 2002
- IOVA 2007
- Country
- VZIO United States
- IOVA United States
- Employees
- VZIO N/A
- IOVA N/A
- Industry
- VZIO Consumer Electronics/Appliances
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VZIO Consumer Staples
- IOVA Health Care
- Exchange
- VZIO Nasdaq
- IOVA Nasdaq
- Market Cap
- VZIO 2.3B
- IOVA 3.6B
- IPO Year
- VZIO 2021
- IOVA N/A
- Fundamental
- Price
- VZIO $11.13
- IOVA $10.07
- Analyst Decision
- VZIO Hold
- IOVA Strong Buy
- Analyst Count
- VZIO 9
- IOVA 10
- Target Price
- VZIO $10.75
- IOVA $24.80
- AVG Volume (30 Days)
- VZIO 2.0M
- IOVA 6.2M
- Earning Date
- VZIO 11-07-2024
- IOVA 11-05-2024
- Dividend Yield
- VZIO N/A
- IOVA N/A
- EPS Growth
- VZIO 57.67
- IOVA N/A
- EPS
- VZIO 0.08
- IOVA N/A
- Revenue
- VZIO $1,719,900,000.00
- IOVA $32,772,000.00
- Revenue This Year
- VZIO $8.45
- IOVA $13,836.92
- Revenue Next Year
- VZIO $9.82
- IOVA $183.20
- P/E Ratio
- VZIO $146.70
- IOVA N/A
- Revenue Growth
- VZIO 0.01
- IOVA 13669.75
- 52 Week Low
- VZIO $4.82
- IOVA $3.21
- 52 Week High
- VZIO $11.30
- IOVA $18.33
- Technical
- Relative Strength Index (RSI)
- VZIO 48.03
- IOVA 44.01
- Support Level
- VZIO $11.20
- IOVA $8.80
- Resistance Level
- VZIO $11.30
- IOVA $11.80
- Average True Range (ATR)
- VZIO 0.07
- IOVA 0.61
- MACD
- VZIO -0.02
- IOVA -0.29
- Stochastic Oscillator
- VZIO 14.29
- IOVA 24.39
About VZIO VIZIO Holding Corp.
VIZIO Holding Corp operates two distinct integrated businesses: Device and Platform+. Through Device business, it offers a range of high-performance Smart TVs designed to address specific consumer preferences, as well as a portfolio of soundbars that deliver immersive audio experiences. It generates revenue from the shipment of these devices to retailers and distributors across the United States, as well as directly to consumers through the website. The Company's reportable segments: Device, and Platform+T. It derives maximum revenue from Device Segment.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.